Treatment of Acinetobacter infections.
Acinetobacter baumannii remains an important and difficult-to-treat pathogen whose resistance patterns result in significant challenges for the clinician. Despite the prevalence and interest in A. baumannii infections, there is relatively limited well-controlled scientific data to help the clinician select optimal empirical and subsequent targeted therapy for a variety of infections. We will review the currently available antimicrobial agents and discuss the clinical data supporting the use of the various agents.
Fishbain
Joel
J
Division of Infectious Diseases, St John Hospital and Medical Center, Detroit, Michigan 48236, USA. Joel.Fishbain@stjohn.org
Peleg
Anton Y
AY
D000151:Acinetobacter Infections / Q000188:drug therapy*; D040981:Acinetobacter baumannii / Q000187:drug effects; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D006801:Humans
D000890:Anti-Infective Agents